A new blood separator device, the Amicus separator developed by Fenwal, has received 510(k) clearance from the US Food & Drug Administration (FDA).

The Fenwal Amicus separator is used to collect platelets and other blood components from donors and is fitted with new wireless data export capabilities, allowing blood centres to easily access procedure information to monitor machine and operator performance.

During clinical trials, the Amicus separator with DXT allows blood centres to increase platelet yield per donor by enabling better analysis of performance by device, operator and collection site, without the added cost or capital investment of rewiring facilities.

The device offers blood-centre professionals easy-to-read, on-demand reports concerning donations at multiple locations, which help identify opportunities for improvement and training.

The Amicus uses barcode scanners to capture kit lot numbers, operator ID and donation ID for each collection procedure, and the information is then sent through a secure wireless connection from the Amicus separator to a server connected through the blood centre’s network.

Fenwal received FDA clearance to market the Amicus separator for collecting platelets stored in Fenwal InterSol platelet additive solution, the first platelet additive solution available in the USA.